Abstract library

31 results for "grades".
#2215 Development of Multiplex Biomarker Assay to Subtype Pancreatic Neuroendocrine Tumors (PanNETs) with Distinct Prognosis and Mutations
Introduction: Overall 5-year survival for PanNETs ranges from 25-100%. The treatment paradigm for PanNETs largely based upon grades, which is significantly heterogeneous. We previously defined three molecular subtypes (distributed grades) of PanNETs using PanNETassigner signature. There is an unmet clinical need for prognostic and predictive biomarkers and clinically-relevant assays to complement grade and improve patient stratification.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: Dr Anguraj Sadanandam
#1114 CT Evaluation of Gastric Neuroendocrine Neoplasm Based on WHO 2010 Classification
Introduction: The 2010 WHO classification classifies GEP-NEN into grade 1, 2 and 3.
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Ying Li
Authors: Li Y, Li Z W, Tang L, Cao K, ...
#1727 Ultrasonography Characteristics of Hepatic Neuroendocrine Neoplasm
Introduction: The incidence of hepatic neuroendocrine neoplasm (HNEN) is significantly increased in recent years.Lack of recognization usually lead to misdiagnosis.
Conference: 14th Annual ENETS conference (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: house physician Xiaona Lin
Authors: Lin X, Chen J, Xu M, Xie X, ...
#1239 Histological Classification of Pancreatic Neuroendocrine Tumours: Optimising the Ki67 System
Introduction: Pancreatic neuroendocrine tumours are graded using the Ki67 antigen in accordance with the WHO 2010 classification. Despite the system’s widespread use, a wide variety of tumour behaviours have been described leading to various proposed revisions.
Conference: 12th Annual ENETS Conference (2015)
Category: Pathology, grading, staging
Presenting Author: Logan Mills
Keywords: G3
#1789 FDG-PET is Superior to WHO Grading in Predicting Overall Survival of Patients with Neuroendocrine Tumors: A Prospective Study of 172 Patients
Introduction: Accurate grading of patients with neuroendocrine tumors (NETs) is essential for risk stratification and optimal choice of therapy. Currently, WHO grading is based on histo-pathologically assessed degree of tumor proliferation.
Conference: 14th Annual ENETS conference (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Professor Andreas Kjær
Keywords: PET, PET/CT, imaging, survival
#127 Sunitinib for the treatment of advanced, progressive pancreatic neuroendocrine tumors
Introduction: Sunitinib is an oral, multitargeted tyrosine kinase inhibitor approved for use in advanced renal cell carcinoma and imatinib-resistant/intolerant gastrointestinal stromal tumors. Investigations of sunitinib in the RIP1-Tag2 mouse model and in phase I/II clinical trials provide evidence of antitumor activity against pancreatic neuroendocrine tumors (NET).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof Eric Raymond
#129 Grade according to Ki-67 or mitotic count in gastroenteropancreatic neuroendocrine tumors
Introduction: Gastroenteropancreatic neuroendocrine tumors (NETs) are uncommon tumors with a reported incidence of 2.5-5 per 100000 population. The recent classification system of NETs proposed by the European Neuroendocrine Tumor Society (ENETS) uses both Ki-67 labelling index and mitotic index to assign grade (low, intermediate, high). It has been adopted into routine practice but there is limited data on the relationship between these indices and their effect on classification.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohid S Khan
#440 The First Neuroendocrine Tumor Methylome Using Methylation-Specific Immunoprecipitation Followed by Second Generation Sequencing – MeDIP-seq
Introduction: Recently, the first cancer methylomes have been created which identified differential methylation at CpG island-shores (2kb upstream of CpG islands) to be of particular importance in the tumourigenic process.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr Christina Thirlwell
Authors: Thirlwell C, Sasmaz S, Dibra H, Feber A, ...
#496 Progression-Free Survival by Prior Somatostatin Analog Use and Primary Tumor Site and Updated Safety Results in Patients with Advanced Neuroendocrine Tumors and a History of Carcinoid Syndrome: A RADIANT-2 Analysis
Introduction: In RADIANT-2, patients (pts) with advanced neuroendocrine tumors (NET) on Everolimus (E, 10 mg/d) + octreotide LAR (O, 30 mg q28d) had clinically meaningful improvement in progression-free survival (PFS) v. placebo (P)+O (16.4 mo v. 11.3 mo, respectively).
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Marianne E Pavel
#592 Expression of PTEN and mTOR in Pancreatic Neuroendocrine Tumors and Their Clinical Significance
Introduction: mTOR is currently under investigation as a potential target for anticancer therapy. Loss of PTEN, the negative regulators of the PI3K-Akt-mTOR pathway, have been associated with cancer.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Xu Han
Authors: Han X, Ji Y, Zhao J, Xu X, ...